Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation - Wikidata - wikimedia - TriplyDB

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation

http://www.wikidata.org/entity/Q34793218

about

Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Afford New Opportunities in Inherited Cardiovascular Disease Modeling Young at Heart: Pioneering Approaches to Model Nonischaemic Cardiomyopathy with Induced Pluripotent Stem Cells G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease Modeling Nanopatterned Human iPSC-Based Model of a Dystrophin-Null Cardiomyopathic Phenotype Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery Stem Cells and Progenitor Cells for Tissue-Engineered Solutions to Congenital Heart Defects Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening Induced pluripotent stem cell-derived cardiomyocytes for cardiovascular disease modeling and drug screening Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias iPSCs and small molecules: a reciprocal effort towards better approaches for drug discovery Induced pluripotent stem cells as a disease modeling and drug screening platform Clinical Potentials of Cardiomyocytes Derived from Patient-Specific Induced Pluripotent Stem Cells Maturation status of sarcomere structure and function in human iPSC-derived cardiac myocytes Atomic force mechanobiology of pluripotent stem cell-derived cardiomyocytes MultiElec: A MATLAB Based Application for MEA Data Analysis Genome-Wide Transcriptome and Binding Sites Analyses Identify Early FOX Expressions for Enhancing Cardiomyogenesis Efficiency of hESC Cultures.A Systemized Approach to Investigate Ca(2+) Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine.Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine Molecular pathogenesis of long QT syndrome type 2 Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes Induced pluripotent stem cell potential in medicine, specifically focused on reproductive medicine Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes Hyperthermia Influences the Effects of Sodium Channel Blocking Drugs in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.High-purity enrichment of functional cardiovascular cells from human iPS cells.The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes.The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients.New iPSC for old long QT syndrome modeling: putting the evidence into perspective.Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia.Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.Modeling Inherited Arrhythmia Disorders Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes.The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications.Low extracellular potassium prolongs repolarization and evokes early afterdepolarization in human induced pluripotent stem cell-derived cardiomyocytes.Induced Pluripotent Stem Cells: Global Research Trends.

P2860

Q26750618-D4F4530F-C5C2-477D-B731-96FF651C9FBE Q26750663-DBD5558B-5A6C-4DEE-974B-D352EE054658 Q26772221-EAC6463C-DC48-47FA-B534-4F1DF7650C4D Q26779454-0CBE35E8-3C2B-4A51-8EE2-EB9EA18B0FD7 Q26781825-FC727318-199A-4D7D-AB5E-85DAEB981F76 Q26785527-D89651C7-D49B-4E32-91E1-279DDBDCF87F Q26798131-E436AD39-1F0D-4C8F-B374-C2241FE71DD3 Q26799470-DF7D3ECC-BED2-47ED-8A8B-DBE3664D34FE Q26828408-D2533030-2539-460C-A7FD-93DF263CC61E Q26853227-D62AB943-092D-4E8D-A299-CBFD1D75F316 Q26865055-555E11A4-99A3-40B3-9181-4ECAA0303A3A Q26865689-16ECBCD4-B0C1-436B-9688-ADDA5994A91E Q27021919-5B50AB7C-D85E-4C3B-B83A-A42A33FF2103 Q27024992-9ECC5207-4A00-4EB6-9645-7BD8831C4CC4 Q27302347-701F2B5F-7F76-4B27-ACD0-5E8302B5AB9D Q27304749-11107D0F-2F0D-4182-8E40-6C7A655738A3 Q27319765-5A2C761F-3FE9-44C2-AE02-BFC98D47E746 Q27330969-04143D00-277A-4B49-8D94-08079A346BEE Q27693850-BC5F821A-1182-4CF1-B92B-D3A966FCA7F4 Q28076397-2B1C3317-4B81-410E-A960-2C367887AC84 Q28077303-87F7CF40-ED57-4CDF-90A8-806DE136BA3D Q28080945-41FCB0D5-19FE-448D-94B4-76CECB5EC8A4 Q28081697-91DEE7C6-B5F6-4363-9C54-0BC82BA210F3 Q28083057-62BC3400-16E7-4853-95B8-3EDF14E514DC Q28255887-2542A52F-AA48-4879-9AC9-D608951D07A4 Q28553287-BD622ECE-7D46-4217-A715-282D800FDB1D Q28818235-7C4BF96E-3F77-46E2-942C-CBA0E0050212 Q30411331-5F304C35-2A53-47E7-BA31-47452FF1FE3F Q30558954-BE7C081B-B388-456C-99F8-FA01A9D04296 Q30645777-3A590B35-CCC2-4E77-B69A-66E5452B508E Q30828413-1B3CC794-666C-4E78-B69A-23FFC263DB9A Q33163102-17280C6C-B096-4129-B266-5C8EDBC373CA Q33163638-91D23365-E5CD-4D97-8349-D3C91476103F Q33163663-BB5212B4-3B75-48DB-9EB0-F446299019F2 Q33164771-140598C3-36AD-4606-89B8-BC0302649BC1 Q33653672-FF58E0CC-6032-4A10-B13B-08CD1F593EE2 Q33704567-CA0AE421-C7F6-4E0C-904B-099AD7E79385 Q33748399-92AE82BD-BAFD-4A67-83B5-73299D7C9513 Q33830565-E4542B98-F6A9-404F-9A9E-F226DED59313 Q33914515-86F2B60B-54EC-4596-8EA5-4299D840B8F1

P2860

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation

http://www.wikidata.org/entity/Q34793218

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@ast

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@en

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@nl

type

label

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@ast

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@en

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@nl

prefLabel

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@ast

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@en

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@nl

P1433

Q34793218-7736A747-CA54-4252-B741-191BF7FDC5CB

P1476

Q34793218-411A6940-3A38-4804-A8AD-D0D612669797

P2093

Q34793218-0D99375A-9A2F-4359-8812-EDDE0AD3659A

Q34793218-3093FC9A-B152-4074-A8EC-029B960109D8

Q34793218-5FBDB1AB-71E3-48A1-94DE-1BDCD262B78F

Q34793218-AD51076F-AB1A-41DD-B211-9B8BFD339D16

Q34793218-BF637B3E-0A0D-40BD-A95A-B1CD1B73182A

Q34793218-CDFAF9A5-525E-4676-8BDD-37776614303B

P2860

Q34793218-09D7C2D3-C3DC-412D-950F-2BF18B9FE5CC

Q34793218-0BD8A8D7-D241-40BD-AA0D-7F9C4EDC0F88

Q34793218-1160BD5E-9165-4EF0-8AAE-12F93BAB2C72

Q34793218-176DD15D-1C38-44C9-8ABF-C38455B4FAC8

Q34793218-271005E2-A77B-4FF4-A139-E716E5E2E274

Q34793218-2BD69D36-6CF5-408E-AAA8-E220065ECA61

Q34793218-30BE7637-67F6-41B0-AC93-8F1BC49FE2FF

Q34793218-3C4B66DD-B3FE-4B9B-80E1-51EAE89E7934

Q34793218-47C5D7BD-E4BF-4464-B195-F28E4D73786A

Q34793218-51A5725A-475D-4A57-A17B-82F5C0CD6E2E

P304

Q34793218-14694703-680C-4AAC-8B34-39CF18A62B0B

P31

Q34793218-440B0B99-6203-44BD-ADB1-0932ABB94392

P356

Q34793218-357AA91C-B398-4A06-8F2A-C14B7727B384

P433

Q34793218-0CE7CA49-6631-4B29-8628-8EEDB0FC3781

P478

Q34793218-69AAA1ED-3256-4502-B930-F7E82E6EFE50

P50

Q34793218-02193667-8118-461D-93D3-1F1B2C4B86C3

P577

Q34793218-5A78D9C8-3295-472B-ACAC-8E69687480AF

P5875

Q34793218-7609D500-534C-407F-A234-C5A0F9419AB0

P698

Q34793218-28A404E2-DB20-4AEF-BA0D-C2FACB9FD849

P921

Q34793218-85D42452-CA92-4EE5-BB20-1508D38D131C

P932

Q34793218-AB281906-D918-4FA3-B655-468A5779A3A0

P356

P1433

European Heart Journal

P1476

Drug evaluation in cardiomyocy ...... ng QT syndrome type 2 mutation

@en

P2093

Andrew Staniforth

http://www.w3.org/2001/XMLSchema#string

Divya Rajamohan

http://www.w3.org/2001/XMLSchema#string

Elena Matsa

http://www.w3.org/2001/XMLSchema#string

Emily Dick

http://www.w3.org/2001/XMLSchema#string

Ian Mellor

http://www.w3.org/2001/XMLSchema#string

Lorraine Young

http://www.w3.org/2001/XMLSchema#string

P2860

Induced pluripotent stem cell lines derived from human somatic cells

Modelling the long QT syndrome with induced pluripotent stem cells

Patient-specific induced pluripotent stem-cell models for long-QT syndrome

Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome.

Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.

Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.

Risk stratification in the long-QT syndrome.

Implantable cardioverter defibrillator in high-risk long QT syndrome patients.

Drug-induced prolongation of the QT interval.

Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.

P304

952-962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/EURHEARTJ/EHR073

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50266822

http://www.w3.org/2001/XMLSchema#string

P698

21367833

http://www.w3.org/2001/XMLSchema#string

P921

Human Induced Pluripotent Stem Cells

P932

3076668

http://www.w3.org/2001/XMLSchema#string